Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

If 2024 was the year local companies acquainted themselves with artificial intelligence, 2025 is shaping up to be the year ...

The Food and Drug Administration (FDA) last week granted the first approval for UK pharma major AstraZeneca’s Datroway ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Record revenue of €4.57bn in 2024, up +6.1% vs. 2023 Estimated 2024 financial results meet communicated targets: Adjusted EBITDA at c. 35.2%Free cash flow slightly above €340m 2024 revenue at €4,573.7 ...

As bird flu continues to threaten animals and public health, the U.S. government has stepped up its response. Experts says it ...

as governments have stopped paying for mass immunisation and the market has transitioned to a conventional commercial model – with a dramatic fall-off in vaccination rates. In March, Moderna’s ...

Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...

and build our commercial business," said Bancel. In the near term, that means driving uptake of Moderna's Spikevax COVID-19 vaccines and recently-approved mResvia for respiratory syncytial virus ...

The life-sciences company expects its capsules and health business to return to growth in 2025, after sales and earnings fell ...